About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral capsules (250 mg)
Drug class
Tyrosine kinase inhibitor
Administration
Take 250 mg twice daily, with or without food. Swallow capsules whole; they should preferably not be chewed, crushed or broken.
Uses
• Metastatic ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC)
• ALK-positive inflammatory myofibroblastic tumor (IMT) that is unresectable, recurrent or treatment-resistant
• ALK-positive anaplastic large-cell lymphoma (ALCL) that is recurrent or treatment-resistant
Competitive advantages
As an ALK and ROS1 inhibitor, crizotinib is an ideal choice, particularly for patients with lung cancer and specific genetic alterations. Through its precise mechanism and genetic targeting, crizotinib provides substantially better clinical outcomes than traditional chemotherapy and can reduce tumor size and improve patients’ quality of life. Its rapid and sustained effectiveness makes it recognized among specialists as an advanced and effective treatment.
Original company product page ↗